Basimglurant for Trigeminal Neuralgia

Not currently recruiting at 62 trial locations

Overseen By Noema Pharma

Age: 18+

Sex: Male

Travel: May Be Covered

Trial Phase: Phase 2 & 3

Sponsor: Noema Pharma AG

Must not be taking: Opioids, Antipsychotics

Disqualifiers: Major psychiatric, Substance abuse, others

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called basimglurant, designed to help people with trigeminal neuralgia (TN), a condition causing severe facial pain. Researchers aim to determine if basimglurant can effectively reduce pain and ensure its safety for patients. Participants will receive either the drug or a placebo (a pill with no active medicine) at different stages to compare results. The trial seeks adults who regularly experience intense TN pain, with at least three severe pain episodes per day. As a Phase 2, Phase 3 trial, this study is crucial for assessing the treatment's effectiveness in a larger group and serves as a final step before potential FDA approval, offering participants a chance to contribute to groundbreaking research.

Will I have to stop taking my current medications?

Yes, you will need to stop taking your current TN pain medication to participate in this trial. However, you can use opioids for pain control as long as it does not exceed 2 days per week.

Is there any evidence suggesting that basimglurant is likely to be safe for humans?

Research shows that basimglurant is under study for safety in people with trigeminal neuralgia, a very painful nerve condition. Previous patients have generally tolerated basimglurant well. Although specific details about side effects in these studies aren't provided, the drug has been tested for other conditions, suggesting it is likely safe enough to proceed to later trial stages. This indicates that past research has found the treatment well-tolerated. However, like any medicine, side effects can occur, so discussing any concerns with a doctor is important. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for trigeminal neuralgia?

Basimglurant is unique because it targets the mGluR5 receptor, a new approach compared to the standard treatments for trigeminal neuralgia, which often include anticonvulsants like carbamazepine or oxcarbazepine. This novel mechanism of action may offer relief for patients who do not respond well to existing medications or experience significant side effects. Researchers are excited about basimglurant's potential to provide a more effective and better-tolerated option for managing the severe pain associated with trigeminal neuralgia.

What evidence suggests that basimglurant might be an effective treatment for trigeminal neuralgia?

Research shows that basimglurant, which participants in this trial may receive, might help reduce pain for people with trigeminal neuralgia (TN). Studies have found that it calms overactive nerve circuits, believed to cause the intense pain in TN. Previous trials demonstrated that basimglurant is safe and well-tolerated by patients. While more information is needed, these findings suggest it could help ease the severe pain linked to TN. ^{1 2 5 6 7}

Are You a Good Fit for This Trial?

Adults aged 18-75 with a confirmed diagnosis of primary trigeminal neuralgia, experiencing significant pain despite current treatments. Participants must be fluent in the study language and capable of giving informed consent. Women must be non-pregnant, non-lactating, and using contraception if of childbearing potential.

Inclusion Criteria

I have been diagnosed with trigeminal neuralgia by a neurologist.

I experience severe pain episodes daily for at least 2 months.

I experience severe pain episodes daily for at least 2 months.

Exclusion Criteria

I have had stomach or small intestine surgery, or a condition that affects how my body absorbs nutrients.

I have not taken antipsychotic medications in the last 6 months.

I haven't had a heart attack, stroke, or major heart surgery in the last 6 months.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Run-in

Participants receive Basimglurant once daily starting at 1.5mg for 8 weeks to evaluate its effect on pain associated with TN

8 weeks

Double-blind Treatment

Participants receive double-blind treatment with Basimglurant or placebo to assess maintenance of effect on pain

12 weeks

Open-label Extension

Participants are offered open-label treatment with Basimglurant to evaluate long-term safety and efficacy

52 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Basimglurant

Trial Overview

The trial is testing the effectiveness and safety of basimglurant (1.5mg - 3.5mg) for adults with trigeminal neuralgia compared to a placebo. The goal is to see if this medication can reduce the intense facial pain associated with TN.

How Is the Trial Designed?

Group I: Arm A: Basimglurant/NOE-101 Experimental Treatment 1 Intervention

* Period 1 (Run-in: Baseline1 to Week 8): Basimglurant once daily dosing starting dose 1.5mg * Period 2 (Double blind: Weeks 9 to 20): Participants will receive double-blind treatment with Basimglurant once daily. * Open-label Extension (OLE): On completion of Period 2, participants will be offered open label treatment with Basimglurant in an open label extension for up to 52 weeks.

Group II: Arm B: Placebo Placebo Group 1 Intervention

\- Period 2 (Double blind: Week 9 to Week 20): Participant randomized to placebo will receive the corresponding number of matching placebo capsules.

Who Is Running the Clinical Trial?

Noema Pharma AG

Lead Sponsor

Trials

6

Recruited

570+

Published Research Related to This Trial

Basimglurant (compound 2) is a potent negative allosteric modulator of mGlu5 that shows similar efficacy to diazepam in anxiety tests but requires significantly lower doses, indicating its potential as a safer alternative for treating anxiety and depression.

CTEP (compound 3) is the first mGlu5 NAM with a long half-life in rodents, making it suitable for chronic studies, which could help in understanding its long-term effects and therapeutic potential.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Metabotropic glutamate receptor 5 negative allosteric modulators: discovery of 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, RO4917523), a promising novel medicine for psychiatric diseases. Jaeschke, G., Kolczewski, S., Spooren, W., et al.[2015]

Basimglurant is a novel mGlu5 negative allosteric modulator showing promising antidepressant-like properties in preclinical studies, with a favorable pharmacological profile that supports its potential use in treating major depressive disorder (MDD).

The drug demonstrates good oral bioavailability, a long half-life for once-daily dosing, and has shown effects on anxiety and pain, suggesting it may also help with common comorbidities associated with MDD.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression. Lindemann, L., Porter, RH., Scharf, SH., et al.[2015]

The study identifies α6 subunit-containing GABAA receptors (α6GABAARs) in trigeminal ganglia as a promising target for migraine treatment, showing that their activation can reduce trigeminal vascular system (TGVS) activation in an animal model of migraine.

Using a selective positive allosteric modulator (PAM) for α6GABAARs, Compound 6, significantly decreased neuronal activation and related migraine markers, suggesting that α6GABAAR-selective PAMs could be developed into effective new migraine therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The α6 subunit-containing GABAA receptor: A novel drug target for inhibition of trigeminal activation. Fan, PC., Lai, TH., Hor, CC., et al.[2021]

Carbamazepine is the first-line treatment for trigeminal neuralgia, but if patients cannot tolerate it, alternative medications like phenytoin, baclofen, and clonazepam can be considered, although their relative effectiveness is not well established.

For patients who do not respond to medication, surgical options like microvascular decompression are recommended for younger patients, while older patients may benefit from radiofrequency thermal rhizotomy, with other techniques available if initial treatments fail.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Trigeminal Neuralgia. Perkin, GD.[2020]

Carbamazepine is the primary treatment for trigeminal neuralgia, showing significant efficacy with a number needed to treat (NNT) of 1.7 for at least 50% pain relief, making it a highly effective option.

Other medications like baclofen and lamotrigine also provide pain relief, with baclofen having an NNT of 1.4, while lamotrigine can enhance relief for patients not fully helped by carbamazepine or phenytoin (NNT = 2.1).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacotherapy of trigeminal neuralgia. Sindrup, SH., Jensen, TS.[2019]

Mavoglurant, a drug targeting metabotropic glutamate receptor subtype-5, was found to be well tolerated in a long-term study with 267 participants (119 adolescents and 148 adults) over up to 34 months, showing no new safety concerns.

While the drug did not show significant behavioral benefits in initial studies, gradual improvements were noted in the open-label extensions, suggesting that further research is needed to explore its efficacy in treating Fragile X syndrome.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents. Hagerman, R., Jacquemont, S., Berry-Kravis, E., et al.[2019]

The study found that the novel mGlu5 receptor antagonist, basimglurant, has an oral bioavailability of approximately 67%, indicating that a significant portion of the drug is effectively absorbed into the bloodstream after oral administration.

Using a double-tracer technique, the research revealed that basimglurant is primarily excreted through urine as metabolites, with a long terminal half-life of 178 hours for the drug's radioactivity, suggesting prolonged effects in the body.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [13C6]-labeled basimglurant in humans. Guerini, E., Schadt, S., Greig, G., et al.[2017]

In a 12-week study involving 183 participants with Fragile X syndrome, the mGluR5 negative allosteric modulator basimglurant did not show significant improvement in behavioral symptoms compared to placebo, particularly at the 0.5 mg dose.

While basimglurant was generally well-tolerated, there was a higher incidence of psychiatric adverse events, including hallucinations, suggesting careful consideration of safety in future trials.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results. Youssef, EA., Berry-Kravis, E., Czech, C., et al.[2018]

Mirogabalin, a medication that targets specific calcium channels, showed promising effectiveness in relieving trigeminal neuropathy symptoms in two postoperative cases after skull base surgery, with one patient experiencing immediate improvement.

These findings suggest that mirogabalin could be a beneficial option for managing postoperative neuropathic pain, but further research with larger patient groups is needed to validate its efficacy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Clinical Effectiveness of Mirogabalin Besylate for Trigeminal Neuropathy after Skull Base Surgery: Illustrative Cases. Karatsu, K., Tamura, R., Miyauchi, T., et al.[2023]

In a study of 18 patients with trigeminal neuralgia, treatment with eslicarbazepine acetate significantly reduced pain intensity from a median score of 9.5 to 2.5 and decreased the frequency of pain episodes from 70 per week to just 0.37, indicating strong efficacy.

Despite some adverse events reported by 61% of patients, 88.9% reported good tolerance to eslicarbazepine, suggesting it is a safe and well-tolerated option for managing trigeminal neuralgia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Assessment of efficacy and safety of eslicarbazepine acetate for the treatment of trigeminal neuralgia. Sanchez-Larsen, A., Sopelana, D., Diaz-Maroto, I., et al.[2019]

Citations

1.

clinicaltrials.gov

clinicaltrials.gov/study/NCT05217628

An Efficacy and Safety Study of Basimglurant (NOE-101) in ...

An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. ClinicalTrials.gov ID NCT05217628. Sponsor Noema Pharma AG.

2.

trialx.com

trialx.com/clinical-trials/listings/254744/an-efficacy-and-safety-study-of-basimglurant-noe-101-in-patients-with-trigeminal-neuralgia/

An Efficacy and Safety Study of Basimglurant (NOE-101) in ...

Clinical trial for Trigeminal Neuralgia , An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia.

3.

clinicaltrials.eu

clinicaltrials.eu/inn/basimglurant/

Basimglurant: A Promising New Drug for Multiple Conditions

The trials are measuring various outcomes, including changes in pain levels for trigeminal neuralgia, reduction in seizure frequency for tuberous sclerosis ...

4.

noemapharma.com

noemapharma.com/pipeline/

Our Pipeline

Reducing the nociceptive circuits at over-signaling, involved in trigeminal neuralgia. Basimglurant (NOE-101) was previously found to be safe and well-tolerated ...

5.

empr.com

empr.com/home/news/drugs-in-the-pipeline/basimglurant-fast-tracked-for-pain-associated-with-trigeminal-neuralgia/

Basimglurant Fast Tracked for Pain Associated with ...

The primary endpoint of the study is time to loss of efficacy or pain recurrence defined as the confirmed increase in the number of weekly ...

6.

euclinicaltrials.eu

euclinicaltrials.eu/ctis-public/view/2024-514497-41-00?lang=en

Clinical Trials in the European Union - EMA

An international randomized clinical study, measuring safety and effectiveness of basimglurant for the treatment of pain in patients with Trigeminal Neuralgia.

7.

bereflected.org

bereflected.org/clinical-trials/listings/340078/an-efficacy-and-safety-2/

An Efficacy and Safety Study of Basimglurant (NOE-101) in ...

This study tests an experimental drug called basimglurant to see if it helps reduce pain and is safe to use.